Your activity: 2 p.v.

Aminocaproic acid: Pediatric drug information

Aminocaproic acid: Pediatric drug information
(For additional information see "Aminocaproic acid: Drug information" and see "Aminocaproic acid: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Amicar
Therapeutic Category
  • Hemostatic Agent
Dosing: Neonatal
Prevention of bleeding associated with extracorporeal membrane oxygenation, high-bleeding risk patients

Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO), high-bleeding risk patients: Limited data available: IV: 100 mg/kg prior to or immediately after cannulation, followed by continuous IV infusion of 25 to 30 mg/kg/hour for up to 72 hours; target activated clotting time (ACT) range during therapy of 180 to 200 seconds has been used (Downard 2003; Horwitz 1998; Wilson 1993); variable results; patients requiring surgery just prior to or while on ECMO seem to benefit most.

Prevention of perioperative bleeding associated with cardiac surgery

Prevention of perioperative bleeding associated with cardiac surgery: Limited data available: IV: 75 mg/kg administered at the beginning and end of cardiopulmonary bypass, along with 75 mg/100 mL added to the priming fluid for cardiopulmonary bypass (Martin 2011).

Dosing: Pediatric
Hematuria, refractory

Hematuria (gross; upper tract), refractory: Limited data available: Children ≥11 years and Adolescents: Oral: 100 mg/kg/dose every 6 hours; continue for 2 days beyond resolution of hematuria; dosing based on case series (n=4) which showed hematuria resolution within 2 to 7 days; risks and benefits must be weighed prior to use (Kaye 2010).

Hemorrhage in patients with hemostatic disorders, adjunct treatment

Hemorrhage (oral, epistaxis, menorrhagia) in patients with hemostatic disorders, adjunct treatment: Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/dose every 6 hours; maximum daily dose: 24 g/day (Acharya 2011).

Mucosal bleeding in thrombocytopenia/platelet dysfunction, treatment

Mucosal bleeding in thrombocytopenia/platelet dysfunction, treatment: Limited data available: Infants, Children, and Adolescents: Oral, IV: 50 to 100 mg/kg/dose every 6 hours; maximum daily dose: 24 g/day (Bussel 2011; Lipton 2011).

Prevention of bleeding associated with dental procedures in hemophilic patients

Prevention of bleeding associated with dental procedures in hemophilic patients: Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/dose every 6 hours; maximum daily dose: 24 g/day; used in conjunction with DDAVP or factor replacement therapy; continue for up to 7 days or until mucosal healing is complete (Acharya 2011).

Prevention of bleeding associated with extracorporeal membrane oxygenation, high-bleeding risk patients

Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO), high-bleeding risk patients: Limited data available: Infants, Children, and Adolescents: IV: 100 mg/kg prior to or immediately after cannulation, followed by a continuous IV infusion of 25 to 30 mg/kg/hour for up to 72 hours; target activated clotting time (ACT) range during therapy of 180 to 200 seconds has been used (Downard 2003; Horwitz 1998; Wilson 1993); variable results; patients requiring surgery just prior to or while on ECMO seem to benefit most.

Prevention of perioperative bleeding

Prevention of perioperative bleeding: Limited data available:

Cardiac surgery with cardiopulmonary bypass:

Infants and Children <2 years: Dosing regimens variable: IV: In the largest trial (n=120, all patients <20 kg), a dose of 75 mg/kg was administered at the beginning and end of cardiopulmonary bypass (CPB), and 75 mg/100 mL was added to the CPB priming fluid (Martin 2011a). Another study group in 2 separate trials (n=110, age range: 2 months to 14 years) used a 100 mg/kg dose after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of 3 doses (Chauhan 2000; Chauhan 2004).

Children ≥2 years and Adolescents: IV: 100 mg/kg after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of 3 doses; regimen used in 2 separate trials (n=110, age range: 2 months to 14 years) (Chauhan 2000; Chauhan 2004).

Craniofacial reconstruction surgery:

Infants ≥6 months to Children ≤2 years: IV: 100 mg/kg administered over 10 minutes, followed by a continuous IV infusion of 40 mg/kg/hour until the end of surgery (ie, completion of skin closure). Dosing based on an open-label, non-randomized, dose escalation, population pharmacokinetic trial (n=18, median age: 39 weeks) (Stricker 2013).

Spinal surgery (eg, idiopathic scoliosis) :

Children ≥11 years and Adolescents: IV: 100 mg/kg (maximum dose: 5 g) administered over 15 to 30 minutes after induction, followed by a continuous IV infusion of 10 mg/kg/hour for the remainder of the surgery; discontinued at time of wound closure (Florentino-Pineda 2001; Florentino-Pineda 2004; Halanski 2014).

Traumatic hyphema

Traumatic hyphema: Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/dose every 4 hours for 5 days; maximum daily dose: 30 g/day (Brandt 2001; Crouch 1999; Teboul 1995).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments are provided in the manufacturer's labeling; aminocaproic acid may accumulate in patients with decreased renal function; use with caution.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments are provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Aminocaproic acid: Drug information")

Acute bleeding

Acute bleeding: Oral, IV: Loading dose: 4 to 5 g during the first hour, followed by 1 g/hour for 8 hours (or 1.25 g/hour using oral solution) or until bleeding is controlled; maximum daily dose: 30 g.

Extracorporeal membrane oxygenation, refractory bleeding

Extracorporeal membrane oxygenation, refractory bleeding (off-label use): IV: Loading dose of 4 to 5 g; followed by an infusion of 1 to 1.25 g/hour until bleeding is controlled (Buckley 2016).

Intracranial hemorrhage associated with thrombolytic treatment

Intracranial hemorrhage associated with thrombolytic treatment (alternative therapy) (off-label use):

Note: Consider for use in addition to cryoprecipitate or when cryoprecipitate is contraindicated in patients who have a symptomatic intracranial hemorrhage after receiving thrombolytic within the past 24 hours (AHA/ASA [Powers 2018]; NCS/SCCM [Frontera 2016]).

IV: Loading dose: 4 to 5 g, followed by 1 g/hour for 8 hours until bleeding is controlled (AHA/ASA [Powers 2018]; NCS/SCCM [Frontera 2016]; Yaghi 2017).

Mouth and mucosal bleeding in patients with hemostatic defects

Mouth and mucosal bleeding in patients with hemostatic defects (eg, hemophilia, von Willebrand disease, other factor deficiencies associated with bleeding) (adjunctive therapy):

Note: Generally, use in conjunction with (and not as a substitute for) replacement of the appropriate clotting factor, especially in individuals with hemophilia. Do not give simultaneously with an activated prothrombin complex concentrate, as this can increase the risk of thromboembolism; if used concurrently, they should be separated by ≥12 hours (WFH [Srivastava 2013]). Consultation with a hemophilia treatment center is advised.

Oral: 50 to 100 mg/kg every 6 hours until wound has healed (NHF MASAC 2020).

Perioperative prevention of blood loss and transfusion

Perioperative prevention of blood loss and transfusion (eg, cardiac surgery, other surgeries with significant blood loss) (off-label use):

Note: Dosing and timing of administration varies widely; use is procedure and institution specific. Recommendations provided below are usual dosage ranges from a variety of surgeries; refer to institutional protocols for details on specific surgeries.

Usual dose and range: IV: Loading dose of 5 to 10 g (or 75 to 150 mg/kg), followed by 1 g/hour (or 10 to 15 mg/kg/hour) until the end of the procedure or up to 8 hours after the procedure (Berenholtz 2009; Gravlee 2008; Li 2017; Verma 2020).

Thrombocytopenia, bleeding

Thrombocytopenia (severe), bleeding (off-label use):

Loading dose: IV: 100 mg/kg (maximum dose: 5 g) over 30 to 60 minutes, followed by 1 g/hour; maximum daily dose: 24 g (Bartholomew 1989; Gardner 1980). When bleeding has ceased, may consider transitioning to maintenance dose.

Maintenance: Oral, IV: 1 to 4 g every 4 to 12 hours; maximum daily dose: 24 g; duration of therapy varies depending on etiology and patient factors, but may continue maintenance dose until platelet count is stable without the need for transfusions and the risk of bleeding is minimized (Antun 2013; Bartholomew 1989; Gardner 1980; Marshall 2016).

Dosing: Kidney Impairment: Adult

May accumulate in patients with decreased renal function. When used during cardiopulmonary bypass in anephric patients, a normal or slightly reduced loading dose and a continuous infusion rate of 5 mg/kg/hour has been recommended (Gravlee 2008).

Dosing: Hepatic Impairment: Adult

No dosage adjustment provided in the manufacturer's labeling.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Generic: 250 mg/mL (20 mL)

Solution, Oral:

Amicar: 25% (236.5 mL) [contains edetate (edta) disodium, methylparaben, propylparaben, saccharin sodium; raspberry flavor]

Generic: 25% (236.5 mL)

Tablet, Oral:

Amicar: 500 mg, 1000 mg [scored]

Generic: 500 mg, 1000 mg

Generic Equivalent Available: US

Yes

Administration: Pediatric

Oral: May administer without regard to food.

Parenteral: Do not administer undiluted; rapid IV injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia.

Intermittent IV infusion: After further dilution, administer over 10 to 60 minutes (rate dependent upon use) (Florentino-Pineda 2001; Florentino-Pineda 2004; Halanski 2014; Stricker 2013; manufacturer's labeling).

Continuous IV infusion: Must further dilute prior to administration.

Administration: Adult

Rapid IV injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia.

IV: May administer loading dose over 15-60 minutes depending on indication; a continuous infusion may be necessary.

Storage/Stability

Store intact vials, tablets, and syrup at 20°C to 25°C (68°F to 77°F). Do not freeze. Solutions diluted for IV use in D5W or NS to concentrations of 10 to 100 mg/mL are stable at 4°C (39°F) and 23°C (73°F) for 7 days (Zhang 1997).

Use

To enhance hemostasis when fibrinolysis contributes to bleeding (causes may include cardiac surgery, hematologic disorders, neoplastic disorders, abruptio placentae, hepatic cirrhosis, and urinary fibrinolysis) (Injection, oral solution, tablets: FDA approved in adults); has also been used for traumatic hyphema, prevention of perioperative bleeding, refractory hematuria, and prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO) in high-risk patients.

Medication Safety Issues
Sound-alike/look-alike issues:

Amicar may be confused with amikacin, Amikin

International issues:

Amicar [US] may be confused with Omacor brand name for Omega-3-Acid Ethyl Esters [multiple international markets]

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.

Cardiovascular: Arrhythmia, bradycardia, edema, hypotension, intracranial hypertension, peripheral ischemia, syncope, thrombosis

Central nervous system: Confusion, delirium, dizziness, fatigue, hallucinations, headache, malaise, seizure, stroke

Dermatologic: Rash, pruritus

Gastrointestinal: Abdominal pain, anorexia, cramps, diarrhea, GI irritation, nausea, vomiting

Genitourinary: Dry ejaculation

Hematologic: Agranulocytosis, bleeding time increased, leukopenia, thrombocytopenia

Local: Injection site necrosis, injection site pain, injection site reactions

Neuromuscular & skeletal: CPK increased, myalgia, myositis, myopathy, rhabdomyolysis (rare), weakness

Ophthalmic: Vision decreased, watery eyes

Otic: Tinnitus

Renal: BUN increased, intrarenal obstruction (glomerular capillary thrombosis), myoglobinuria (rare), renal failure (rare)

Respiratory: Dyspnea, nasal congestion, pulmonary embolism

Miscellaneous: Allergic reaction, anaphylactoid reaction, anaphylaxis

Postmarketing and/or case reports: Hepatic lesion, hyperkalemia, myocardial lesion

Contraindications

Disseminated intravascular coagulation (without heparin); evidence of an active intravascular clotting process.

Warnings/Precautions

Concerns related to adverse effects:

• Intrarenal obstruction: May occur secondary to glomerular capillary thrombosis or clots in the renal pelvis and ureters; do not use in hematuria of upper urinary tract origin unless possible benefits outweigh risks.

• Skeletal muscle weakness: Ranging from mild myalgias and fatigue to severe myopathy with rhabdomyolysis and acute renal failure has been reported with prolonged use. Monitor CPK; discontinue treatment with a rise in CPK.

Disease-related concerns:

• Renal impairment: Use with caution in patients with renal impairment; may accumulate.

Concurrent drug therapy issues:

• Blood products: Do not administer with factor IX complex concentrates or anti-inhibitor coagulant complexes; may increase risk for thrombosis.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

Other warnings/precautions:

• Appropriate use: Do not administer without a definite diagnosis of laboratory findings indicative of hyperfibrinolysis. Inhibition of fibrinolysis may promote clotting or thrombosis; more likely due to the presence of disseminated intravascular coagulation.

• IV administration: Avoid rapid IV administration; may induce hypotension, bradycardia, or arrhythmia; rapid injection of undiluted solution is not recommended.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program

Anti-inhibitor Coagulant Complex (Human): Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). Risk X: Avoid combination

Factor IX Complex (Human) [(Factors II, IX, X)]: Antifibrinolytic Agents may enhance the adverse/toxic effect of Factor IX Complex (Human) [(Factors II, IX, X)]. Specifically, the risk for thrombosis may be increased. Risk X: Avoid combination

Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]: Antifibrinolytic Agents may enhance the adverse/toxic effect of Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]. Specifically, the risk for thrombosis may be increased. Risk X: Avoid combination

Tretinoin (Systemic): May enhance the thrombogenic effect of Antifibrinolytic Agents. Management: Concomitant use of antifibrinolytics and tretinoin is not recommended. If combined, monitor patients closely for any signs of thrombotic complications. Risk D: Consider therapy modification

Pregnancy Considerations

Animal reproduction studies have not been conducted.

Monitoring Parameters

Fibrinogen, fibrin split products, serum creatinine kinase (long-term therapy); serum potassium, BUN, creatinine.

Reference Range

Therapeutic concentration: >130 mcg/mL (concentration necessary for inhibition of fibrinolysis).

Mechanism of Action

Binds competitively to plasminogen; blocking the binding of plasminogen to fibrin and the subsequent conversion to plasmin, resulting in inhibition of fibrin degradation (fibrinolysis).

Pharmacokinetics (Adult data unless noted)

Onset of action: ~1 to 72 hours

Distribution: Widely through intravascular and extravascular compartments; Vd: Oral: 23 L; IV: 30 L

Metabolism: Minimally hepatic

Bioavailability: Oral: 100%

Half-life elimination: 1 to 2 hours

Time to peak: Oral: 1.2 ± 0.45 hours

Excretion: Urine (65% as unchanged drug, 11% as metabolite)

Pricing: US

Solution (Amicar Oral)

0.25 g/mL (per mL): $14.18

Solution (Aminocaproic Acid Intravenous)

250 mg/mL (per mL): $0.33 - $0.54

Solution (Aminocaproic Acid Oral)

0.25 g/mL (per mL): $12.76 - $13.47

Tablets (Amicar Oral)

500 mg (per each): $24.43

1000 mg (per each): $48.86

Tablets (Aminocaproic Acid Oral)

500 mg (per each): $7.16 - $33.50

1000 mg (per each): $13.55 - $43.98

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Acepramin (HN, HU);
  • Acidum e-aminocapronicum (PL);
  • AKK (UA);
  • Amicar (AE, AU, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE, ZA);
  • Caproamin (VE);
  • Caprolest (NL);
  • Caprolex (BD);
  • Caprolisin (IT);
  • EAC (DE);
  • Epsamon (CH);
  • Epsicaprom (PT);
  • Epsikapron (SA);
  • Epsilon (FI);
  • Hamostat (IN);
  • Hemocid (IN);
  • Hemolysin (BD);
  • Hexalense (FR);
  • Inselon (TW);
  • Ipsilon (AR, BR, JP, PY, UY);
  • Kai Nai Yin (CN);
  • Minocap (BD);
  • Plaslloid (TW);
  • Resplamin (JP);
  • Syrop acidi e-aminocapronici (PL)


For country code abbreviations (show table)
  1. Acharya S, "Hemostatic Disorders," Manual of Pediatric Hematology and Oncology, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 402-3.
  2. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  3. Amicar (aminocaproic acid) [prescribing information]. Lake Forest, IL: Clover Pharmaceuticals; March 2017.
  4. Aminocaproic acid injection solution [prescribing information]. Lehi, UT: Civica, Inc; May 2020.
  5. Aminocaproic acid injection solution [prescribing information]. Shirley, NY: American Regent, Inc; May 2020.
  6. Antun AG, Gleason S, Arellano M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013;119(21):3784-3787. doi:10.1002/cncr.28253 [PubMed 23921838]
  7. Banerjee A, Stoica C, and Walia A, "Acute Hyperkalemia as a Complication of Intravenous Therapy With Epsilon-Aminocaproic Acid," J Clin Anesth, 2011, 23(7):565-8. [PubMed 22050802]
  8. Bartholomew JR, Salgia R, and Bell WR, “Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid,” Arch Intern Med, 1989, 149(9):1959-61. [PubMed 2774776]
  9. Berenholtz SM, Pham JC, Garrett-Mayer E, et al. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine (Phila Pa 1976). 2009;34(19):2096-2103. doi:10.1097/BRS.0b013e3181b1fab2 [PubMed 19730217]
  10. Brandt MT and Haug RH, "Traumatic Hyphema: A Comprehensive Review," J Oral Maxillofac Surg, 2001, 59(12):1462-70. [PubMed 11732035]
  11. Buckley LF, Reardon DP, Camp PC, et al. Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: four adult case reports and a review of the literature. Heart Lung. 2016;45(3):232-236. [PubMed 26907195]
  12. Bussel J and Renaud T, "Disorders of Platelets," Manual of Pediatric Hematology and Oncology, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 372.
  13. Casati V, Guzzon D, Oppizzi M, et al, “Hemostatic Effects of Aprotinin, Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Cardiac Surgery,” Ann Thorac Surg, 1999, 68(6):2252-57. [PubMed 10617012]
  14. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  15. Chauhan S, Das SN, Bisoi A, et al, “Comparison of Epsilon Aminocaproic Acid and Tranexamic Acid in Pediatric Cardiac Surgery,” J Cardiothorac Vasc Anesth, 2004, 18(2):141-43. [PubMed 15073700]
  16. Chauhan S, Kumar BA, Rao BH, et al, "Efficacy of Aprotinin, Epsilon Aminocaproic Acid, or Combination in Cyanotic Heart Disease," Ann Thorac Surg, 2000, 70(4):1308-12. [PubMed 11081890]
  17. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737. [PubMed 22556195]
  18. Crouch ER Jr and Crouch ER, "Management of Traumatic Hyphema: Therapeutic Options," J Pediatr Ophthalmol Strabismus, 1999, 36(5):238-50. [PubMed 10505828]
  19. Crouch ER Jr, Williams PB, Gray MK, et al, “Topical Aminocaproic Acid in the Treatment of Traumatic Hyphema,” Arch Ophthalmol, 1997, 115(9):1106-12. [PubMed 9298049]
  20. Daily PO, Lamphere JA, Dembitsky WP, et al, “Effect of Prophylactic Epsilon-Aminocaproic Acid on Blood Loss and Transfusion Requirements in Patients Undergoing First-time Coronary Artery Bypass Grafting: A Randomized, Prospective, Double-Blind Study,” J Thorac Cardiovasc Surg, 1994, 108(1):99-108. [PubMed 8028387]
  21. Diringer MN, Bleck TP, Hemphill JC 3rd, et al; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211-240. [PubMed 21773873]
  22. Downard CD, Betit P, Chang RW, et al, "Impact of AMICAR on Hemorrhagic Complications of ECMO: A Ten-Year Review," J Pediatr Surg, 2003, 38(8):1212-6. [PubMed 12891495]
  23. Eaton MP, “Antifibrinolytic Therapy in Surgery for Congenital Heart Disease,” Anest Analg, 2008, 106(4):1087-100. [PubMed 18349177]
  24. Eberle B, Mayer E, Hafner G, et al, “High-Dose Epsilon-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations,” Ann Thorac Surg, 1998, 65(3):667-73. [PubMed 9527193]
  25. Fergusson DA, Hebert PC, Mazer CD, et al, “A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery,” N Engl J Med, 2008, 358(22):2319-31. [PubMed 18480196]
  26. Florentino-Pineda I, Blakemore LC, Thompson GH, et al, "The Effect of Epsilon-Aminocaproic Acid on Perioperative Blood Loss in Patients With Idiopathic Scoliosis Undergoing Posterior Spinal Fusion: A Preliminary Prospective Study," Spine (Phila Pa 1976), 2001, 26(10):1147-51. [PubMed 11413428]
  27. Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al, "The Effect of Amicar on Perioperative Blood Loss in Idiopathic Scoliosis: The Results of a Prospective, Randomized Double-Blind Study," Spine (Phila Pa 1976), 2004, 29(3):233-8. [PubMed 14752343]
  28. Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46. [PubMed 26714677]
  29. Gardner FH and Helmer RE 3rd, “Aminocaproic Acid. Use in Control of Hemorrhage in Patients With Amegakaryocytic Thrombocytopenia,” JAMA, 1980, 243(1):35-7. [PubMed 6965311]
  30. Gravlee GP and Spiess B, "Pharmacologic Prophylaxis for Post-Cardiopulmonary Bypass Bleeding," Cardiopulmonary Bypass: Principles and Practice, 3rd ed, Philadelphia, PA: Lippincott Williams & Wilkins, 2008, 522-42.
  31. Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  32. Halanski MA, Cassidy JA, Hetzel S, Reischmann D, Hassan N. The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double-blinded pilot study. Spine Deform. 2014;2(3):191-197. [PubMed 27927417]
  33. Haut MT, Mauro VF, and Davis HH, “Effect of Renal Failure and Hemodialysis on Aminocaproic Acid Plasma Concentrations,” DICP, 1989, 23(11):922-3. [PubMed 2596137]
  34. Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 124(23):2610-42. [PubMed 22064600]
  35. Horwitz JR, Cofer BR, Warner BW, et al, "A Multicenter Trial of 6-Aminocaproic Acid (Amicar) in the Prevention of Bleeding in Infants on ECMO," J Pediatr Surg, 1998, 33(11):1610-3. [PubMed 9856877]
  36. Hui FK, Schuette AJ, Lieber M, et al. ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients. Neurosurgery. 2012;70(3):702-705; discussion 705-706. doi:10.1227/NEU.0b013e3182358cca [PubMed 21904257]
  37. Kaye JD, Smith EA, Kirsch AJ, et al, "Preliminary Experience With Epsilon Aminocaproic Acid for Treatment of Intractable Upper Tract Hematuria in Children With Hematological Disorders," J Urol, 2010, 184(3):1152-7. [PubMed 20650477]
  38. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  39. Kikura M, Levy JH, Tanaka KA, et al, “A Double-Blind, Placebo-Controlled Trial of Epsilon-Aminocaproic Acid for Reducing Blood Loss in Coronary Artery Bypass Grafting Surgery,” J Am Coll Surg, 2006, 202(2):216-22. [PubMed 16427545]
  40. Li G, Sun TW, Luo G, Zhang C. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis. Eur Spine J. 2017;26(1):140-154. doi:10.1007/s00586-016-4792-x [PubMed 27671279]
  41. Lipton JM, "Bone Marrow Failure," Manual of Pediatric Hematology and Oncology, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 131.
  42. Lucas ON and Albert TW, “Epsilon Aminocaproic Acid in Hemophiliacs Undergoing Dental Extractions: A Concise Review,” Oral Surg Oral Med Oral Pathol, 1981, 51(2):115-20. [PubMed 6782532]
  43. Mannucci P, “Hemostatic Drugs,” N Engl J Med, 1998, 339(4):245-53. [PubMed 9673304]
  44. Marshall A, Li A, Drucker A, Dzik W. Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. Hematol Oncol. 2016;34(3):147-153. doi:10.1002/hon.2189 [PubMed 25641349]
  45. Martin K, Breuer T, Gertler R, et al, "Tranexamic Acid Versus ε-Aminocaproic Acid: Efficacy and Safety in Paediatric Cardiac Surgery," Eur J Cardiothorac Surg, 2011a, 39(6):892-7. [PubMed 21115357]
  46. Martin K, Gertler R, Liermann H, et al, "Switch From Aprotinin to ε-Aminocaproic Acid: Impact on Blood Loss, Transfusion, and Clinical Outcome in Neonates Undergoing Cardiac Surgery," Br J Anaesth, 2011, 107(6):934-9. [PubMed 21857014]
  47. McGetrick JJ, Jampol LM, Goldberg MP, et al, “Aminocaproic Acid Decreases Secondary Hemorrhage After Traumatic Hyphema,” Arch Ophthalmol, 1983, 101(7):1031-3. [PubMed 6870623]
  48. National Hemophilia Foundation. MASAC document 263 - MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-263-masac-recommendations-concerning-products-licensed-for-the-treatment-of-hemophilia-and-other-bleeding-disorders. Updated August 2020.
  49. Nzerue CM and Falana B, "Refractory Hyperkalaemia Associated With Use of Epsilon-Aminocaproic Acid During Coronary Bypass in a Dialysis Patient," Nephrol Dial Transplant, 2002, 17(6):1150-1. [PubMed 12032221]
  50. Patatanian E and Fugate SE,, “Hemostatic Mouthwashes in Anticoagulated Patients Undergoing Dental Extraction,” Ann Pharmacother, 2006, 40(12):2205-10. [PubMed 17090725]
  51. Penta de Peppo A, Pierri MD, Scafuri A, et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J. 1995;22(3):231-236. [PubMed 7580360]
  52. Pieramici DJ, Goldberg MF, Melia M, et al, “A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial of Topical Aminocaproic Acid (Caprogel) in the Management of Traumatic Hyphema,” Ophthalmology, 2003, 110(11):2106-12. [PubMed 14597516]
  53. Pinosky ML, Kennedy DJ, Fishman RL, et al, “Tranexamic Acid Reduces Bleeding After Cardiopulmonary Bypass When Compared to Epsilon Aminocaproic Acid and Placebo,” J Card Surg, 1997, 12(5):330-8. [PubMed 9635271]
  54. Post R, Germans MR, Tjerkstra MA, et al; ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021;397(10269):112-118. doi:10.1016/S0140-6736(20)32518-6 [PubMed 33357465]
  55. Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158 [PubMed 29367334]
  56. Sane DC, Califf RM, Topol EJ, et al, " Bleeding During Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management," Ann Intern Med, 1989, 111(12):1010-22. [PubMed 2688504]
  57. Singer RJ, Ogilvy CS, Rordorf G. Aneurysmal subarachnoid hemorrhage: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 16, 2022.
  58. Souto JC, Olover A, Zuazu-Jausoro I, et al, “Oral Surgery in Anticoagulated Patients Without Reducing the Dose of Oral Anticoagulant: A Prospective Randomized Study,” J Oral Maxillofac Surg, 1996, 54(1):27-32. [PubMed 8530996]
  59. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment guidelines working group on behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47. doi:10.1111/j.1365-2516.2012.02909.x [PubMed 22776238]
  60. Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke. 2008;39(9):2617-2621. [PubMed 18658042]
  61. Stricker PA, Zuppa AF, Fiadjoe JE, et al. Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery. Br J Anaesth. 2013;110(5):788-799. [PubMed 23353035]
  62. Suarez JI. Diagnosis and management of subarachnoid hemorrhage. Continuum (Minneap Minn). 2015;21(5 Neurocritical Care):1263-1287. doi:10.1212/CON.0000000000000217 [PubMed 26426230]
  63. Teboul BK, Jacob JL, Barsoum-Homsy M, et al, “Clinical Evaluation of Aminocaproic Acid for Managing Traumatic Hyphema in Children,” Ophthalmology, 1995, 102(11):1646-53. [PubMed 9098257]
  64. Vander Salm TJ, Kaur S, Lancey RA, et al, “Reduction of Bleeding After Heart Operations Through the Prophylactic Use of Epsilon-Aminocaproic Acid,” J Thorac Cardiovasc Surg, 1996, 112(4):1098-107 [PubMed 8873738]
  65. Verma S, Srinivas U, Sathpathy AK, Mittal P. Comparison of effectiveness of tranexamic acid and epsilon-amino-caproic-acid in decreasing postoperative bleeding in off-pump CABG surgeries: a prospective, randomized, double-blind study. Ann Card Anaesth. 2020;23(1):65-69. doi:10.4103/aca.ACA_142_18 [PubMed 31929250]
  66. Walton W, Von Hagen S, Grigorian R, et al, “Management of Traumatic Hyphema,” Surv Ophthalmol, 2002, 47(4):297-334. [PubMed 12161209]
  67. Williams GD, Bratton SL, Riley EC, et al, "Efficacy of Epsilon-Aminocaproic Acid in Children Undergoing Cardiac Surgery," J Cardiothorac Vasc Anesth, 1999, 13(3):304-8. [PubMed 10392682]
  68. Wilson JM, Bower LK, Fackler JC, et al, "Aminocaproic Acid Decreases the Incidence of Intracranial Hemorrhage and Other Hemorrhagic Complications of ECMO," J Pediatr Surg, 1993, 28(4):536-40. [PubMed 8483066]
  69. Yaghi S, Willey JZ, Cucchiara B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48(12):e343-e361. doi:10.1161/STR.0000000000000152 [PubMed 29097489]
  70. Zhang YP and Trissel LA, “Stability of Aminocaproic Acid Injection Admixtures in 5% Dextrose Injection and 0.9% Sodium Chloride Injection,” Int J Pharm Compound, 1997, 1(2):132-4.
Topic 12564 Version 257.0